
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aspartyl-alanyl-diketopiperazine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ampio Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India
Details : The study will utilize inhaled Ampion™ to treat those suffering from respiratory distress due to COVID-19. Top-line results also showed that Ampion reduced all-cause mortality in COVID-19 respiratory distress by 78% for COVID-19 respiratory distress.
Product Name : Ampion
Product Type : Amino Acid
Upfront Cash : Inapplicable
June 15, 2021
Lead Product(s) : Aspartyl-alanyl-diketopiperazine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
